Nanoparticles Contract Manufacturing Market Report 2025

This Nanoparticles Contract Manufacturing market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The nanoparticles contract manufacturing market size has grown rapidly in recent years. It will grow from $3.27 billion in 2024 to $3.7 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to a rising preference for contract manufacturing, increasing need for nanomaterials across various applications, increased usage of therapeutics drug delivery applications, rising demand for nanomedicine, and demand for high-quality nanoparticles.

The nanoparticles contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $6.04 billion in 2029 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to increasing knowledge about pharmaceutical delivery systems, advancement in nanotechnology and materials science, demand for advanced drug delivery systems, high demand for metal nanoparticles in cancer therapy, and rapid growth of pharmaceutical companies. Major trends in the forecast period include strategic partnership among industry leaders, technological advancement, the shift towards sustainable and eco-friendly nanoparticle production methods, integration of nanoparticles in food and beverage packaging, and integration of technology.

The increasing allocation of resources towards research activities is poised to drive the expansion of the nanoparticle contract manufacturing market. Research investments encompass financial support directed at conducting studies to advance scientific knowledge, develop innovative technologies, and address specific challenges. Several factors contribute to the rise in research investments, including a focus on innovation, heightened awareness of societal issues, backing for emerging technologies, supportive policies, and government funding initiatives. These investments are instrumental in advancing nanoparticle contract manufacturing by fostering technological innovation, enabling customization, ensuring quality control, facilitating scalability, encouraging interdisciplinary collaboration, expanding market reach, and fostering economic development. For example, the UK government announced a substantial increase in public Research and Development (R&D) expenditures in April 2023, with plans to elevate the budget to £22 billion ($27.64 billion) by fiscal year 2024-2025, demonstrating a commitment to enhancing R&D efforts and promoting innovation domestically.

Key players in the nanoparticle contract manufacturing market are leveraging innovative technologies, such as commercial formulation systems, to produce medicines for clinical and commercial purposes and maintain a competitive advantage. Commercial formulation systems provide comprehensive platforms for efficient development and production of nanoparticle-based products. For instance, Cytiva, a US-based provider of life sciences products and solutions, introduced the NanoAssemblr commercial formulation system in July 2023. This system minimizes the risk of cross-contamination, particularly crucial for genomic medicines, by employing a single-use fluid path. It enhances production efficiency by reducing downtime for sanitization and cleaning, enabling the manufacture of multiple lipid nanoparticle products within the same facility. The system features 21 CFR Part 11-compliant software for electronic batch records, real-time monitoring of flow rate, and automated processes such as priming, calibration, formulation, and in-line dilution.

In February 2022, Merck KGaA, a Germany-based technology company, acquired Exelead Inc. for $780 million. This acquisition allows Merck to strengthen its mRNA capabilities and solidify its position as a leading contract development and manufacturing organization in the mRNA vaccine and therapeutic sector. Exelead Inc., a US-based biopharmaceutical company, specializes in lipid nanoparticles (LNP) and complex injectable formulations, with a focus on mRNA therapeutics.

Major companies operating in the nanoparticles contract manufacturing market are AstraZeneca plc, Evonik Industries AG, Emergent BioSolutions Inc., CordenPharma International GmbH, Ajinomoto Bio-Pharma Services, IBA Worldwide, BioVectra Inc., Mevion Medical Systems Inc., Fortis Life Sciences, Ascendia Pharmaceuticals LLC, LSNE Contract Manufacturing, Precision NanoSystems Inc., Ardena Holding NV, American Elements, Polymun Scientific Immunbiologische Forschung GmbH, Danfysik A/S, Hitachi Chemical Advanced Therapeutics Solutions LLC, Axolabs GmbH, AVANSA Technology & Services, Cytodiagnostics Inc., Encapsula NanoSciences LLC, MyBiotech GmbH, Nanochemazone, RiboPro GmbH, TechNano India.

North America was the largest region in the nanoparticles contract manufacturing market in 2024. The regions covered in the nanoparticles contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nanoparticles contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nanoparticle contract manufacturing involves outsourcing the production of nanoparticles to third-party manufacturers or contract manufacturing organizations (CMOs). These services offer a versatile solution for various industries, providing customized nanoparticle formulations and expertise to meet specific application requirements and drive innovation across diverse fields.

The primary types of the nanoparticle contract manufacturing market include metal nanoparticles, lipid nanoparticles, and other nanoparticles. Metal nanoparticles are minute particles of metal typically ranging from 1 to 100 nanometers in size. These nanoparticles are manufactured at various scales, including commercial, clinical, and pre-clinical, for applications such as therapeutics, diagnostics, and vaccines. They are utilized by various end-users, including pharmaceutical and biotechnology companies.

The nanoparticles contract manufacturing market research report is one of a series of new reports that provides nanoparticles contract manufacturing market statistics, including nanoparticles contract manufacturing industry global market size, regional shares, competitors with a nanoparticles contract manufacturing market share, detailed nanoparticles contract manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the nanoparticles contract manufacturing industry. This nanoparticles contract manufacturing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nanoparticle contract manufacturing market includes revenues earned by entities by providing services such as custom synthesis, scale-up production, and surface modification and functionalization and related drug delivery nanoparticles, diagnostic nanoparticles, cosmetic nanoparticles, and electronic nanoparticles. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.